Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
On demand webinar

Defining the right digital strategy for oncology: What do you want to measure?

In this webinar, find out how to optimise oncology clinical trials using digital tools to accelerate decision-making.

Oncology clinical trials present some of the most complex challenges across clinical research, impacting enrolment, efficiency, and access. Thankfully, our industry is afforded a unique opportunity to address these issues with the evolving regulatory landscape, the burgeoning field of digital health technologies (DHTs), and the increasing adoption of decentralised and digital trial methods.

The US Food and Drug Administration (FDA)’s recent guidance on Direct-to-Patient (DTP) approaches, electronic Patient-Reported Outcomes (ePROs), and DHTs paves the way for incorporating patient-centric digital tools into trials.

According to PwC, the use of DHTs in clinical trials has grown by 97 percent within the last five years, and Tufts recognises that the appetite for collecting digital endpoints has doubled every three years since 2015.

As DHTs begin to help researchers define the new normal, it’s important to have the right strategy to define how you collect the right data to improve efficiency and experience. 

Learn how top 10 pharmaceutical companies are using a combination of DHTs, ePROs, clinical trial platforms and more, to ease oncology research and drastically reduce timelines. 

Key learning points

  • The right questions to ask your team to help define a digital strategy as part of your clinical development programme. 
  • Why the expanded use of digital measures and biomarkers will continue to accelerate clinical development timelines.
  • How global pharmaceutical companies are benefiting from Medable’s novel approaches and technology to accelerate decision-making in oncology.

OUR SPEAKER

Musaddiq Khan – Vice President, Customer Value – Digital Outcomes & TA Strategy at Medable

Musaddiq Khan (Muz) is Vice President, Customer Value – Digital Outcomes & TA Strategy. He has been involved in clinical research for over 17 years. Most recently, he was the Director of Clinical Program Operations in the exploratory medicine & pharmacology group at Eli Lilly, where he led the operational delivery of the First-in-Human study on Lilly’s COVID-19 Antibody programme. Throughout his career, Muz has held various clinical operations roles in pharma, including PAREXEL, Roche and AstraZeneca. Muz completed his Executive MBA from the University of Cambridge with a dissertation on ‘Developing a Digital Health Strategy for Early Clinical Development’.

Dr Sachin Shah

Dr. Sachin Shah – Digital Biomarker Lead – GSK

Sachin is a medical doctor by background that has been in the digital health space for the last 6 years. A mixture of start up and large organisations Sachin has experience in ideating and creating digital both D2C and B2B solutions. Recently his role focuses on using his expertise in the clinical validation of DHTs to introduce them into clinical trials alongside drug development to augment the evidence dossier by having regulators accept these digital measurements suitable for digital endpoints as primary to secondary endpoints in ph3 trials.

Daniel Cantillon

Daniel Cantillon, MD – Masimo

Dr. Dan Cantillon is an adult EP cardiologist and Chief Medical Officer at Masimo Corporation, a medical device company based in Irvine, CA specializing in non-invasive patient monitoring. Previously, Dr. Cantillon practiced medicine at Cleveland Clinic for over 16 years with multiple leadership roles including departmental research as well as the enterprise-wide Medical Director of Cleveland Clinic’s remote patient monitoring command center for the main campus and regional hospitals serving over 2,000 continuously monitored patients. His clinical achievements include the first-in-US implant of a dual chamber leadless cardiac pacemaker, and the first-in-human implant of an entirely leadless pacemaker-defibrillator. His original research contributions include lead or senior authorship in the New England Journal of Medicine, Journal of the American Medical Association among other leading cardiology journals and practice guidelines. He is a past recipient of Cleveland Clinic’s prestigious Sones-Favaloro Innovation Award for his work in remote patient monitoring.

FAQs

FAQs 

Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

 What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.